State of the Art Review

Reimbursement of Digital Therapeutics: Future Perspectives in Korea

Jin Han Ju, MHA1, Boram Sim, PhD1, Jeongeun Lee, MCH1, and Jin Yong Lee, MD, PhD, MHA1,2,3

1HIRA Research Institute, Health Insurance Review & Assessment Service, Wonju, Korea
2Public Healthcare Center, Seoul National University Hospital, Seoul, Korea
3Department of Health Policy and Management, Seoul National University College of Medicine, Seoul, Korea

AUTHOR'S SUMMARY

Although the global digital therapeutics (DTx) market is rapidly growing and whether the health insurance system will cover DTx is a very important issue, there are currently no standards in Korea after the approval stage of the Ministry of Food and Drug Safety. Regarding this issue, this study examined the concepts and characteristics of DTx and compared major countries (the U.S., the U.K., Germany, Japan, and Australia) reimbursement policies for DTx, thus clarifying the political implications for introducing DTx in Korea.

ABSTRACT

Digital health is rapidly growing worldwide and its area is expanding from wellness to treatment due to digital therapeutics (DTx). This study compared DTx in the Korean context with other countries to better understand its political and practical implications. DTx is generally the same internationally, often categorized as software as a medical device. It provides evidence-based therapeutic interventions for medical disabilities and diseases. Abroad, DTx support entailed state subsidies and fundraising and national health insurance coverage. In the case of national health insurance coverage, most cases were applied to mental diseases. Moreover, in Japan, DTx related to hypertension will possibly be under discussion for national health insurance coverage in 2022. In overseas countries, coverage was decided only when the clinical effects were equivalent to those provided by existing technology, and in the UK, real usage data for DTx and associated evaluations were reflected by national health coverage determination. Prices were either determined through closed negotiations with health insurance operating agencies and manufacturers or established based on existing technology. Concerning the current situation, DTx dealing with various diseases including hypertension are expected to be developed near in the future, and the demand for use and compensation will likely increase. Therefore, it is urgent to define and prepare for DTx, relevant support systems, and health insurance coverage listings. Several support systems must be considered, including government subsidies, science/technology funds, and health insurance.

Keywords: Digital therapeutics; National Health Insurance; Korea
INTRODUCTION

Today, as the digital revolution is becoming a global trend, the importance of digital healthcare that combines information and communication technology and health care services is rapidly increasing worldwide. Moreover, Pear Therapeutics’ digital therapeutics (DTx) “reSET” for the treatment of substance use disorder was approved by the US Food and Drug Administration (FDA) for the first time in the world,\(^1\) digital healthcare is expanding from wellness to disease prevention or management and even treatment. Especially, as awareness of non-contact healthcare has improved due to coronavirus disease 2019 (COVID-19) pandemic, interest in DTx that treat patients using digital technologies such as smartphones and wearable devices has increased significantly.\(^2\)

Compared to the time and monetary resources required for new drug development, DTx entails shorter periods and lower costs. DTx can also provide efficient healthcare services without the need for patient waiting times.\(^3,4\) Currently, DTx are mostly developed to treat mental health, but the treatment areas are expanding to include chronic diseases such as hypertension and diabetes. The prevalence of chronic diseases is continuously increasing, causing the social burden of chronic diseases to also increase significantly.\(^5\) Chronic diseases are closely related to lifestyle such as physical activity, smoking, and eating habits. Thus, maintaining a healthy lifestyle is very important in managing chronic diseases.\(^6\) As DTx can help manage chronic diseases by modifying lifestyle changes, it is expected that the use of DTx can reduce the socio-economic burden of chronic diseases. Thus, DTx is expected to meet new medical demands and create value in terms of the economy, and many countries are preparing policies to support DTx. In fact, FDA has recently eased its regulations on digital technologies to improve access to medical services under the constraints of COVID-19.\(^7\) Germany has also laid legislative groundwork for expanded digital technology usage, including the declaration of the Digital Healthcare Act (Digital-Versorgung-Gesetz) in 2019.\(^8\)

Korea is also supporting the digital health market through the “Korean version of the Digital New Deal” policy, the regulatory innovation policy for medical devices, and Research and Development investment by government agencies. Regarding DTx, the Korean Ministry of Food and Drug Safety (MFDS) has published the Guideline on Review and Approval of DTx, thus making efforts to support the use of DTx.\(^9\) However there are currently no devices approved by the MFDS. Moreover, there is no standard in Korea after the approval stage of MFDS. The National Health Insurance (NHI) system accounts for a large amount of the total health finance, whether the health insurance system will cover DTx is a very important issue.

Based on the above, this study examined the concepts and characteristics of DTx and reviewed major countries’ reimbursement policies for DTx, thus clarifying the political implications for introducing DTx in Korea.

CONCEPT OF DIGITAL THERAPEUTICS

According to the Digital Therapeutics Alliance (DTA), DTx is defined as high-quality software that provides evidence-based therapeutic interventions designed to prevent, manage, and treat medical disabilities and diseases.\(^10\) The use of DTx also requires demonstrable clinically therapeutic effects and approval from specific regulatory authorities (e.g., when drugs are prescribed).\(^20\) In addition, DTx may be provided by various types of technologies such as
mobile applications, virtual reality, and games. In the case of DTx in the form of mobile application, it may be used as shown in Figure 1. Doctors establish treatment plans using DTx according to the patient’s condition. When doctors prescribe DTx, patients download the DTx and activate it using an access code to conduct treatment in their homes. Because DTx usage data is stored in a database, doctors can provide medical advice based on data gathered by DTx and it might be reflected in the treatment at the next visit.  

DTx provides non-invasive treatment, thus they are mainly used in the treatment of neurological or mental health problems such as panic disorder or depression. Furthermore, DTx can be used to prevent deterioration of disease by providing lifestyle guidance for chronic disease patients. For example, high blood pressure is generally related to lifestyle habits such as excessive sodium intake, obesity, smoking, and drinking. Therefore, the optimal blood pressure can be achieved through lifestyle modification, but this depends on patients’ sustained self-management. An app that measures and monitors body weight and provides customized fitness or training plans for patients with high blood pressure leads to lifestyle changes and provides secondary precautions for patients with cardiovascular disease.  

REGULATORY FRAMEWORK OF DIGITAL THERAPEUTICS

In Korea, the MFDS Guideline on Review and Approval of DTx establishes DTx as software as a medical device that provides evidence-based therapeutic interventions designed to prevent, manage, and treat medical disorders and diseases. Meanwhile, the Medical Device Act defines DTx as a form of medical device. The MFDS guidelines outline the scope of DTx based on both the International Classification of Diseases (ICD) and Korean Standard Classification of Diseases (KCD), and it is considered a program that is installed for use with general hardware (e.g., PCs and mobile devices). In addition, some DTx requires a prescription from a medical doctor, just as in the case of drugs or medical devices.
The US Policy for Device/Software Functions and Mobile Medical Applications defines DTx as a form of software application (mobile medical application) that is used to diagnose, treat, alleviate, and/or prevent diseases or other issues affecting the human body. According to the Federal Food, Drug, and Cosmetic Act, standards equivalent to the existing medical devices are applied with the classification in the range of class I–III, with most DTx applications considered class II medical devices. In the US, DTx can be used by patients or healthcare provider.\(^{16}\)

In the UK, there are comprehensive regulations on digital health products. In this case, there is no separate definition for DTx, as all such products are regulated as medical devices.\(^{17}\) However, the Improving Access to Psychological Therapies (IAPT) program defines DTx as a digitally enabled therapy provided through the internet under the guidance of clinicians and which is utilized as a secondary tool to aid treatments provided by healthcare professionals.\(^{18,19}\)

Germany declared the Digital Healthcare Act in 2019 to define DTx. Therein, DTx is described as a low-risk medical device (class I or IIa) that diagnoses, monitors, treats, and/or alleviates diseases or supports these functions. Prior to implementation, any DTx application must first be listed on Germany’s digital health app. Patients are also required to receive a DTx prescription from their doctor or therapist or prove their corresponding indication.\(^{15}\)

In Japan, DTx is defined as a software program that contributes to the diagnosis, treatment, and prevention of diseases according to the software as a medical device guideline of the Ministry of Health, Labor and Welfare. Any such application is regulated as a medical device (class I–IV). Most of the DTx can either be used by healthcare professionals or directly by patients that are supervised by healthcare professionals.\(^{20,21}\)

In Australia, DTx is defined as software that diagnoses, prevents, monitors, treats, and/or alleviates disease/injury or which controls and/or monitors anatomical or physiological functions of the body in accordance with the Therapeutic Goods Act and Software as a Medical Device Guidelines of the Therapeutic Goods Administration. Any such application is regulated as a medical device (class I–III). In Australia, DTx does not necessarily require implementation by a healthcare professional, but the class designation is lowered one level thereupon.\(^{22}\)

Table 1 shows a list comparing these elements by country.

| Category | South Korea | US | UK | Germany | Japan | Australia |
|----------|-------------|----|----|---------|-------|-----------|
| Definition | Software as a medical device that provides evidence-based therapeutic interventions to prevent, manage, and treat medical disorders or diseases | Software applications (mobile medical applications) for diagnosis/treatment/alleviation/prevention of diseases affecting the human body | Digital health products (IAPT) Digitally enabled therapy provided via the internet under the guidance of clinicians | Low-risk medical device that provides diagnosis/monitoring/treatment/alleviation of diseases or supports these functions based on digital technology | Software program that contributes to the diagnosis, treatment, and prevention of diseases | Software program that provides diagnosis, prevention, monitoring, treatment or alleviation of disease or injuries or control/monitoring of anatomical or physiological functions of the body |
| Classification | Medical device | Medical device (class II in most cases) | Medical device | Low-risk medical device (class I, IIa) | Medical device | Medical device (class I–III)* |
| User | Used by patient according to the doctor’s prescription | Used by patient or healthcare provider | Used as an aiding tool for treatment among healthcare professionals | Used only by the patient* or by the patient and the healthcare provider | Used by the healthcare provider or patients under the supervision of healthcare professionals | Used by healthcare provider or individual |

IAPT = improving access to psychological therapies.

*When used by healthcare professionals, the medical device class is lowered by one level for application; *When patient indications are clearly demonstrated.
In Korea, DTx can be supported through the systems of Innovative Health Technology and Conditionally Approved Health Technology, both of which are operated by the National Evidence-based Healthcare Collaborating Agency (NECA). Innovative Health technology is that which has received safety approval but is considered to have insufficient efficacy as determined by the New Health Technology Assessment. Such technologies can be selected when a “statement on the potential of health technology” is additionally submitted for application via the New Health Technology Assessment. Innovative Health Technologies are assigned preliminary classification codes so that temporary coverage of Korean NHI can be applied for three to five years, with clinical effectiveness re-evaluated thereafter. Meanwhile, a Conditionally Approved Health Technology is determined as a Research Stage Technology through the New Health Technology Assessment. In such cases, there are no problems in terms of safety. Further, the technology in question is deemed a priority in terms of the need for clinical implementation. For such types, government subsidies are provided for a set period based on a designation issued by the Minister of Health and Welfare.

In the US, a representative policy for DTx support is the Medicare Coverage of Innovative Technology (MCIT) program developed by Centers for Medicare and Medicaid Services (CMS). The MCIT program supports the market application of Breakthrough Devices; among products designated as such, the program is specifically intended for those that have obtained FDA Premarket Approval, including DTx. Manufacturers can apply for the MCIT program within two years following FDA approval (including authorization). Devices that are eligible for the program are allowed nationwide coverage for four years at the commercial level. After this, MCIT devices are assessed for National Coverage Determination (NCD), Local Coverage Determination (LCD), and claim-by-claim adjudication, according to the existing coverage determination procedure. Manufacturers wishing for NCD must submit data for coverage applications in the third year of the MCIT program. If a manufacturer does not wish to apply for NCD, LCD, or claim-by-claim adjudication, then their situation is assessed by the Medicare Administrative Contractor, which has been given the authority to establish LCD. However, the MCIT policy, which is slated for implementation in December 2021 was repealed in November 2021 for reasons such as evidence development or patient safety and CMS plans to develop another coverage policy to support DTx.

In the UK, the representative DTx support policy includes the NHS England Test Beds Programme, which handles clinical trials and collects real-world test data (Real-World-Testing) for digital health products, and the MedTech Funding Mandate policy (MTFM), which aims to reduce the financial burdens of new technologies, especially by assessing whether products that have acquired National Institute for Health and Care Excellence (NICE) approval reduce costs. In the case of the Test Beds Programme, funds are jointly raised by the Department of Health and Social Care, Office for Life Sciences, NHS England, and NHS Improvement; different levels of financial support may be provided depending on the size of the participating company. In the MTFM, the lowest price among the actual product cost, nominated supply cost, reference price set by NHS England and NHS improvement is used to set the product price. The NHS Commissioners provide funding support for a four-year period by paying the cost for the healthcare service provider that is purchasing the applicable product from the manufacturer.
Germany provides financial support for the development of DTx through the Innovation Fund (Innovationsfonds), which is funded by German Health Insurance (Gesetzlicher Krankenversicherung, GKV). The Innovation Fund aims to both improve the supply of medical services and provide new medical services. Meanwhile, the Innovation Committee operates under Gemeinsame Bundesausschuss, and specifies the areas and standards of application, thus determining the recipients of support and paying accordingly. The Innovation Fund can support up to 100% of the total development costs, but funding is provided only when support is necessary.8

Japan announced Digital Transformation action strategies in healthcare for SaMD called “DASH for SaMD” to support the establishment of a foundation for DTx development in 2020. While there is support for unifying channels, specific financial support programs have not been described to date.31

In Australia, the National Digital Health Strategy indicates that the use of mobile apps can improve patient access to medical information, enhance quality, and ensure efficient healthcare services. Accordingly, Australia tests the clinical or economic effects of DTx through various pilot programs.32 For example, according to the University of Canberra’s pilot program “Mobile health: Empowering people with type 2 diabetes using digital tools” most patients’ diabetes status improved during the program, and the diabetes management app was found to be cost-effective.33 However, there are no clear financial support programs for DTx mentioned at the government level. Table 2 shows the financial support policies for DTx by country.

### STANDARDS AND PROCEDURES FOR DIGITAL THERAPEUTICS COVERAGE DETERMINATIONS

In Korea, there are no dedicated standards and procedures for coverage determination as related to DTx. In the same manner of application for existing medical devices, the coverage status for approved DTx is determined through the New Health Technology Assessment conducted by NECA, assessed by the Health Insurance Review and Assessment Service (HIRA), and reviewed by the Health Insurance Policy Committee. Final coverage status is

| Table 2. Financial support policies for digital therapeutics by country |
|---------------------------|--------------------------|----------------|----------------|----------------|-------------------|------------------|-------------------|
| **Support policy**        | South Korea              | US             | UK             | Germany        | Japan†          | Australia‡        |
| **Aim of policies**       | Innovative Health Technology System | Conditionally Approved Health Technology System | MCIT* | TestBeds | MTFM | Innovation Fund (Innovationsfonds) | NA | NA |
| **Support Method**        | Innovative Health Technology System (selective coverage for 3–5 years) | Conditionally Approved Health Technology System (governmental subsidies) | Cost of product use over 4 years | (TestBeds) Clinical trials and collection of real-world testing data | (MTFM) Reducing cost burdens for new technology development, Testing budget saving effects | Development costs supported through government subsidies | NA | NA |

MCIT = Medicare Coverage of Innovative Technology; MTFM = MedTech Funding Mandate Policy; NA = not applicable.

*MCIT was repealed in November 2021; †Japan supports approval process of digital therapeutics through ‘DASH for SaMD’. However, a clear financial support policy has not been mentioned yet; ‡Various pilot programs are implemented as part of Australia’s digital strategy, but clear financial support policies at the government level have not been mentioned.
determined by notice of the Ministry of Health and Welfare. Clinical safety and effectiveness are also evaluated in the New Health Technology Assessment; however, usability testing is not currently considered. Coverage determination is done in the same manner that applies to existing medical devices, in which coverage is determined when both adequacy of coverage and economic efficiency have been demonstrated. In Korea, there have been no cases in which a DTx application has received MFDS approval and a health insurance coverage determination (Figure 2).

In the US, applications for Medicare coverage are assessed by CMS after FDA approval. There are no separate standards or procedures for coverage determinations pertaining to DTx; rather, existing NCD standards and procedures apply. In the case of NCD, coverage is determined when it is deemed both reasonable and necessary; the following criteria are used for healthcare services: 1) must be safe and effective; 2) should not be experimental or investigational; and 3) adequacy should be satisfied (duration, frequency of use, compliance with standard medical practice, provision of the service in an appropriate environment, provision of the service by qualified healthcare professionals, status of oversupply, demonstration of equivalent or superior effects when compared to existing technology). Any price is set during closed negotiations that consider the market value, development cost, and production cost. The NCD process takes approximately nine to twelve months, ranging from application to coverage determination (Figure 2). While DTx applications have received FDA approval, none have been granted coverage by CMS.

In the UK, approval must first be received from the Medicines and Healthcare Products Regulatory Agency (MHRA). Coverage is then determined by NHS England upon evaluation by the NICE. To date, the IAPT program has been tasked with granting DTx coverage. This entails a 14-week product review period, followed by a 2-year period in which real-world test data are collected; thereafter, coverage is determined upon the completion of a final six-week period of empirical testing, given its success. Product reviews require assessments for contents, clinical effects, and cost-utility, with the results (Improving Access to Psychological Therapies Assessment Briefings) used a basis for proceeding to the components involving the collection of real-world data and empirical testing (Figure 2). Based on the results of the real-world data collection process and evaluation, the Improving Access to Psychological Therapies Evaluation in Practice Report is published to cover factors such as symptoms, accessibility, patient waiting times, treatment rates, and the level of patient satisfaction. Coverage is granted if the DTx is deemed to have an effect equivalent or superior effect when compared to the relevant existing technology and is cost-effective or shows superior clinical effects.

In Germany, DTx coverage is determined through a three-month evaluation conducted by the Federal Institute of Medicines and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), which operates under the Digital Healthcare Act. DTx coverage is divided into temporary and formal listings. It is possible to achieve a formal listing upon demonstrating positive healthcare effects and meeting 124 device requirements (e.g., safety and suitability for use, data protection, information security, interoperability, device...
Figure 2. Health insurance coverage determination process for DTx by country.

DTx = digital therapeutics; IAPT = improving access to psychological therapies; PICO = Population, Intervention, Comparator and Outcome.
robustness, consumer protection, usability, support for healthcare provider, healthcare content quality, patients safety). A temporary listing may be granted for a duration of one year when only the device requirements are satisfied, but a formal listing can only be obtained in such cases if positive healthcare effects are verified during the same period (Figure 2). DTx pricing is set using a similar method that applies to medicines. Here, DTx prices are annually determined through closed negotiations between the German health insurance agency (GKV-Spizerverband) and the respective DTx manufacturers. If a price negotiation fails, then the arbitration committee determines the price within a three-month period. GKV-Spizerverband and the DTx manufacturer in question then renegotiate the price one year from the date of this determination. For a temporary listing, the prices of medicines or products with similar effects to the DTx are used as references to set the maximum price. The cost submitted by the manufacturer is reimbursed for one year, then determined through closed negotiations. In Germany, DTx has been listed for use in various fields, including mental disease, tinnitus, stroke, cancer, and obesity. Currently, 18 DTx devices are on temporary listings, while six devices are on formal listings.

In Japan, approval must first be received by the Pharmaceuticals and Medical Devices Agency. This is conducted in the same manner that applies to the existing treatment materials. DTx coverage is then determined after evaluation by the Health Insurance Treatment Materials Special Committee under the Ministry of Health, Labour and Welfare of Japan as well as review and approval by the Central Social Insurance and Medical Council. Treatment materials are classified into group A (reimbursement is comprehensively included within the existing treatment reimbursement score), group B (separate reimbursement), group C (corresponding to New Health Technology), and group F (non-coverage). DTx applications are also classified into one of these groups at the time of application for coverage, which is granted based on an evaluation of similar functions, new functions, manufacturing costs, import costs, and cost effectiveness (Figure 2). There are two pricing methods. The first pertains to situations in which existing devices can be used as points of reference, followed by a moderation process to set the base price. In cases where there are no similar functions, the base price is set according to various relevant factors, including manufacturing, imports, sales, administrative issues, operations, distribution, consumption, and local consumption taxes. Once a base price has been established, the final price is determined after making adjustments, taking into consideration average prices overseas. Looking at currently listed DTx products, one supports smoking cessation treatment, with coverage determined as group C in terms of the treatment materials. The price was determined based on the service fees (i.e., fees for the management of nicotine dependence). Moreover, DTx for hypertension management will possibly be under discussion for health insurance coverage in 2022.

Australia has not established separate standards and procedures for making coverage determinations relevant to DTx. Rather, such determinations are made in the same manner used for existing medical devices where coverage is determined by the Department of Health when safety, effectiveness, and cost-utility have been demonstrated after a four-to-six-month evaluation conducted by the Medical Services Advisory Committee (Figure 2). Currently, there are no known cases in which coverage listings have been granted to DTx products. DTx coverage determination standards and DTx application cases by country are summarized in Tables 3 and 4, respectively.
KEY LESSONS LEARNED

Most of the current health insurance listed cases are about mental health. However, like Germany and Japan, DTx in various areas, including hypertension or diabetes management can be developed and covered by national health insurance in the near future. Therefore, according to the Korean situation, it is necessary to prepare this in advance at the national level.

Regarding the concept of DTx, Korea uses a similar definition to those employed in the US, UK, Germany, Japan, and Australia. DTx is also regulated as a form of medical device in Korea. As for relevant financial support, two representative reimbursement methods are used outside Korea: 1) government subsidies or fundraising and 2) applications for health insurance coverage. Although details of support methods used in countries such as the US, UK, and Germany are different in various areas, each country operates a system in which the development or usage costs are supported to reduce the financial burdens related to DTx.

In the US, financial support for DTx usage through MCIT was planned but unfortunately repealed in November 2021. In the UK and Germany, support is either provided at the cost level for a certain period or government subsidies and funds are garnered to support the development or usage costs. In Korea, the Innovative Health Technology system currently permits financial support for clinical trials and clinical use, but reimbursements are not fully

Table 3. Digital therapeutics coverage determination standards by country

| Category                        | South Korea | US          | UK                                     | Germany                       | Japan | Australia |
|---------------------------------|-------------|-------------|----------------------------------------|-------------------------------|-------|-----------|
| Government department           | Decision (Ministry of Health and Welfare), Assessment (Health Insurance Review and Assessment) | Centers for Medicare and Medicaid Services | Decision (National Health Service) Assessment (National Institute for Health and Care Excellence) | Decision (GKV) Assessment (BfArM) | Ministry of Health, Labour and Welfare of Japan | Decision (Department of Health) Assessment (MSAC) |
| Status of health insurance coverage | NA          | NA          | △ (Conditional application*)          | ○                             | ○     | NA        |
| Indications                     | NA          | NA          | Mental disease                        | Various diseases, including mental disease, tinnitus, stroke, cancer, and obesity | Smoking cessation treatment | NA        |
| Coverage determination          | Equivalent to the existing medical device (when the adequacy of coverage and economic feasibility have been demonstrated) | Equivalent to the existing medical device (when equivalence to the existing technology or superior performance has been demonstrated) | When the effect is equivalent to or better than the existing technology and a cost-efficient or superior clinical effect is verified | When the 124 product requirements are satisfied, and a clinical effect has been demonstrated | Equivalent to the existing treatment materials (e.g., classification validity, similar functions, new functions, manufacturing cost, import cost, cost-utility) | Equivalent to the existing medical services (when safety, effectiveness, and cost effectiveness have been demonstrated) |
| Usability test                  | NA          | NA          | ○                                      | Decision is made through negotiations in consideration of market values and development/production costs (non-disclosure) | Decision is made in consideration of outcomes based on collected data | Decision is made through closed negotiations between the German health insurance agency and manufacturers (annual renegotiations) | When there is existing technology, the decision is made based on this. When there is no existing technology, the decision is made based on cost calculations |
| Pricing method                  | NA          | NA          | ○                                      | NA                             | NA    | NA        |

*BfArM = Bundesinstitut für Arzneimittel und Medizinprodukte; MSAC = Medical Services Advisory Committee; NA = not applicable. *GKV-Spizenverband; †Health insurance coverage is permitted when it is still possible to monitor the patient even after they have discontinued their treatment, there is still sufficient communication between healthcare professionals and the patient, and a clear support plan has been established by the healthcare professionals.
processed due to the difficulty of setting standards. In addition, burdens may be imposed on the national health insurance budget. To fully implement DTx within the Innovative Health Technology system, Korean policymakers should refer to examples such as the MTFM used in the UK and the temporary listings system used in Germany, both of which provide support through reimbursements at cost levels for set periods. As in the case of the UK TestBeds program, in which support projects are run by multi-ministerial budgets, or the Innovation Fund in Germany, support for DTx can also be provided by government subsidies or fundraising.

In countries outside Korea, DTx coverage determination standards and procedures are applied based on existing medical devices or medical procedures. Coverage is considered when DTx applications are demonstrably equivalent to or better than their existing technological counterparts. For reimbursements, coverage is applied in the same manner used for drugs or medical devices in the UK and Germany, however it is applied according to

| Name of country | Name of device | Method of coverage application | Method of reimbursement | Price |
|-----------------|----------------|-------------------------------|-------------------------|-------|
| UK              | Space          | Conditional listing*          | Fee for use of product  | £297.5 (90 days) |
|                 |                |                               |                         | £743.75 (90 days) |
| Germany         | Deprexis       | Formal listing                | Fee for use of product  | £599 (90 days)   |
|                 | Elevida        |                               |                         | £464 (90 days)   |
|                 | HelloBetter    |                               |                         | £476 (90 days)   |
|                 | Somnio         |                               |                         | £476 (90 days)   |
|                 | Velibra        |                               |                         | £476 (90 days)   |
|                 | Vorvida        |                               |                         | £476 (90 days)   |
|                 | CANKADO        | Temporary listing             |                         | £499.8 (90 days) |
|                 | PRO-React Onco |                               |                         | £345.1 (90 days) |
|                 | Companion patella |                           |                         | £249.86 (90 days) |
|                 | SELFIPAY*      |                               |                         | £540 (90 days)   |
|                 | Invirto        |                               |                         | £428.8 (1 year)  |
|                 | Kalmeda        |                               |                         | £116.97 (90 days) |
|                 | Mawendo        |                               |                         | £119         |
|                 | M-sense        |                               |                         | £219.98 (90 days) |
|                 | Migrane        |                               |                         | £419 (90 days)   |
|                 | Mika           | CBT, monitoring of stress/    |                         | £576 (90 days)   |
|                 | Mindable       | symptoms/adverse events       |                         | £239 (90 days)* |
|                 | NichtraucherHelden |                         |                         | £249 (90 days)   |
|                 | Novego         | CBT                           |                         | £249 (90 days)   |
|                 | Oviva Direkt fur Adipositas |                     |                         | £499 (90 days)   |
|                 | Rehappy        | CBT                           |                         | £239.97 (90 days) |
|                 | VivIRA         | CBT                           |                         | £299 (90 days)   |
|                 | Zanadio        | CBT                           |                         | £499.8 (90 days) |
| Japan           | CureApp        | Support for smoking cessation (provision of messages or video) | Formal listing | ¥ 24,500 |

CBT = cognitive behavioral therapy.
*Individually registered for each indication (3 devices); †€0 is paid when used less than twice; ‡€99 is paid per 90 days in case of re-prescription; §€299 is paid per 90 days in cases of re-prescription.
medical procedures in Japan. Meanwhile, pricing is determined through closed negotiations or depending on the presence of an existing technology; medical benefits or cost information that can be applied are also referred to when estimating price. Rather than establishing separate standards for introducing DTx into the national health insurance system in Korea, it would be more reasonable to determine health insurance coverage according to existing standards and procedures. However, in terms of reimbursements for medical devices in Korea, payments are usually made by including the healthcare service fees. Considering that DTx is treated similarly to drugs (e.g., usage requires a prescription), the remaining challenges are establishing pricing and determining the details of reimbursement. In this regard, policymakers should apply the existing standards used to reimburse the costs of drugs and treatment materials. When DTx is used as a tool to aid in the application of medical services provided by doctors, it may be best to implement a combined reimbursement method that includes service fees and costs of treatment materials.

In the UK, usability assessments are considered when making DTx coverage determinations. Apart from the clinical effects, real-world testing is highly important, but usability assessments are not currently considered in the process used by the New Health Technology Assessment in Korea. This highlights the need to improve the current system by establishing an additional procedure for testing and verifying the actual effects of DTx under the New Health Technology or Innovative Health Technology systems. However, it is also necessary to adjust the assessment period in consideration of the rapid pace at which software changes are often implemented. While countries such as the UK and Germany apply a one- or two-year period, the New Health Technology Assessment and Innovative Health Technology systems in Korea apply a much longer period of three to five years. In this regard, the prompt adoption of DTx requires a shorter the assessment period; this process demands clear specifications and selection criteria to prevent indiscriminate approval and entry.

CONCLUSION

In countries outside Korea, DTx is financially supported through two representative methods, including 1) government subsidies, or fundraising and 2) the application of health insurance coverage. Currently, costs are a major problem in the utilization of digital health technologies, which highlights the need for a financial support system aimed at the provision of non-contact healthcare in Korea. However, the overall budget impacts must be considered when applying health insurance coverage for DTx. The future direction for relevant support in Korea should include 1) cost-level reimbursements for a set period for Innovative Health Technology and 2) financial support through government subsidies or fundraising. From a long-term perspective, the application of health insurance coverage for DTx requires a reimbursement system that considers the value of DTx rather than the cost. This entails a condition in which validation is achieved through real-world testing. In this regard, either a council should be organized to lead the coverage determination process, or a dedicated assessment committee should be established.

REFERENCES

1. Pear Therapeutics, Inc. Pear therapeutics press release [Internet]. Boston (MA): Pear Therapeutics; 2021 [cited 2021 September 22]. Available from: https://peartherapeutics.com/fda-obtains-fda-clearance-first-prescription-digital-therapeutic-treat-disease/.
2. Golinelli D, Boetto E, Carullo G, Nuzzolese AG, Landini MP, Fantini MP. Adoption of digital technologies in health care during the COVID-19 pandemic: systematic review of early scientific literature. *J Med Internet Res* 2020;22:e22280.

3. Kataria S, Ravindran V. Digital health: a new dimension in rheumatology patient care. *Rheumatol Int* 2018;38:1949-57.

4. Kim HS. Apprehensions about excessive belief in digital therapeutics: points of concern excluding merits. *J Korean Med Sci* 2020;35:e373.

5. Shim JS, Oh K, Jung SJ, Kim HC. Self-reported diet management and adherence to dietary guidelines in Korean adults with hypertension. *Korean Cir J* 2020;50:432-40.

6. Cheung BMY, Or B, Fei Y, Tsoi MF. A 2020 vision of hypertension. *Korean Cir J* 2020;50:469-75.

7. U.S. Food and Drug Administration. Enforcement policy for digital health devices for treating psychiatric disorders during the coronavirus disease 2019 (COVID-19) public health emergency [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2020 [cited 2021 March 27]. Available from: https://www.fda.gov/media/136939/download.

8. Gesetzesbeschluss des Deutschen Bundestages (Legislature, German Federal Parliament). Gesetz für eine bessere Versorgung durch Digitalisierung und Innovation (Digitale-Versorgung-Gesetz - DVG) (Nov. 29, 2019).

9. Ministry of Food and Drug Safety. Guidelines on review and approval of digital therapeutics [Internet]. Cheongju: Ministry of Food and Drug Safety; 2020 [cited 2021 March 27]. Available from: https://www.mfds.go.kr/eng/brd/m_40/view.do?seq=72624&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1.

10. Digital Therapeutics Alliance. Digital therapeutics definition and core principles [Internet]. [place unknown]: Digital Therapeutics Alliance; 2019 [cited 2021 March 27]. Available from: https://dtxalliance.org/wp-content/uploads/2021/01/DTA_DTx-Definition-and-Core-Principles.pdf.

11. Bundesinstitut für Arzneimittel und Medizinprodukte. DiGA [Internet]. Bonn: Bundesinstitut für Arzneimittel und Medizinprodukte; 2021 [cited 2021 May 27]. Available from: https://diga.bfarm.de/.

12. CureApp, Inc. CureApp hypertension therapeutics app clinical trial results announced at ESC congress 2021 and published in the European Heart Journal, a leading cardiovascular journal [Internet]. Tokyo: CureApp, Inc.; 2021 [cited 2021 September 22]. Available from: https://cureapp-en.blogspot.com/.

13. Jeon YW, Kim HC. Factors associated with awareness, treatment, and control rate of hypertension among Korean young adults aged 30–49 years. *Korean Cir J* 2020;50:1077-91.

14. Lee HY, Oh GC, Sohn IS, et al. Suboptimal management status of younger hypertensive population in Korea. *Korean Cir J* 2021;51:598-606.

15. Bundesinstitut für Arzneimittel und Medizinprodukte. The fast-track process for digital health applications (DiGA) according to section 19e SGB V [Internet]. Bonn: Bundesinstitut für Arzneimittel und Medizinprodukte; 2020 [cited 2021 April 13]. Available from: https://www.bfarm.de/SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.html.

16. U.S. Food and Drug Administration. Policy for device software functions and mobile medical applications [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2019 [cited 2021 March 27]. Available from: https://www.fda.gov/media/80958/download.

17. National Institute for Health and Care Excellence. Evidence standards framework for digital health technologies [Internet]. London: National Institute for Health and Care Excellence; 2019 [cited 2021 March 27]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf.

18. National Health Services. NHS mental health implementation plan 2019/20-2023/24 [Internet]. London: National Health Services; 2019 [cited 2021 March 27]. Available from: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/07/nhs-mental-health-implementation-plan-2019-2023-24.pdf.

19. National Health Services. The improving access to psychological therapies manual [Internet]. London: National Health Services; 2018 [cited 2021 April 13]. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/06/the-iapt-manual-v5.pdf.

20. Ministry of Health, Labour and Welfare of Japan. Guidelines for medical device applicability of the program [Internet]. Tokyo: Ministry of Health, Labour and Welfare of Japan; 2021 [cited 2021 April 13]. Available from: https://www.mhlw.go.jp/content/11120000/000764274.pdf.
21. Australian Therapeutic Goods Act 1989, Pub. L. No. 21, 1990 (Jan 1, 2019).
22. Therapeutic Goods Administration. How the TGA regulates software based medical devices [Internet]. Woden: Therapeutic Goods Administration; 2021 [cited 2021 April 20]. Available from: https://www.tga.gov.au/sites/default/files/how-tga-regulates-software-based-medical-devices.pdf.
23. National Evidence-based Healthcare Collaborating Agency. Guidance to new healthcare technology evaluation system A to Z [Internet]. Seoul: National Evidence-based Healthcare Collaborating Agency; 2020 [cited 2021 May 25]. Available from: https://nhtra.neca.re.kr/nhtra/publication/nhtra00605V.cog?seq=8975.
24. Centers for Medicare & Medicaid Services. Medicare program; Medicare Coverage of Innovative Technology (MCIT) and definition of “Reasonable and Necessary”; Delay of effective date. Final rules. Fed Regist 2021;86:2987-3010.
25. Centers for Medicare & Medicaid Services. Medicare program; Medicare Coverage of Innovative Technology (MCIT) and definition of “Reasonable and Necessary.” Final rules. Fed Regist 2021;86:2944-58.
26. National Health Services. Test beds programme information to support the launch of wave 2 [Internet]. London: National Health Services; 2018 [cited 2021 April 21]. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/04/test-beds-supporting-information-wave-2-competition.pdf.
27. National Health Services. MedTech funding mandate policy 2021/22 [Internet]. London: National Health Services; 2021 [cited 2021 April 21]. Available from: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2021/01/mtfm-policy-guidance-jan-2021.pdf.
28. National Health Services. 2020/21 National tariff payment system [Internet]. London: National Health Services; 2020 [cited 2021 April 21]. Available from: https://www.england.nhs.uk/wp-content/uploads/2021/02/20-21_National-Tariff-Payment-System.pdf.
29. Gemeinsamer Bundesausschuss Innovationsausschuss. Förderbekanntmachung Seite des Innovationsausschusses beim Gemeinsamen Bundesausschuss zur themenoffenen Forderung von neuen Versorgungsformen gemäß § 92a Absatz 1 des Fuften Buches Sozialgesetzbuch (SGB V) zur Weiterentwicklung der Versorgung in der gesetzlichen Krankenversicherung (zweistufiges Verfahren) [Internet]. Berlin: Gemeinsamer Bundesausschuss Innovationsausschuss; 2021 [cited 2021 April 13]. Available from: https://innovationsfonds.g-ba.de/downloads/media/245/2021-03-17_Foerderbekanntmachung_NVF_themenoffen_2021.pdf.
30. Ministry of Health, Labour and Welfare of Japan. DX (Digital Transformation) action strategies in healthcare for SaMD (Software as a Medical Device) [Internet]. Tokyo: Ministry of Health, Labour and Welfare of Japan; 2020 [cited 2021 April 13]. Available from: https://www.mhlw.go.jp/content/11124500/00075470.pdf.
31. Australian Government, Australian Digital Health Agency. Australia’s national digital health strategy [Internet]. Sydney: Australian Digital Health Agency; 2017 [cited 2021 May 25]. Available from: https://apo.org.au/sites/default/files/resource-files/2017-08/apo-nid182181.pdf.
32. University of Canberra. Mobile health: empowering people with type 2 diabetes using digital tools [Internet]. Canberra: University of Canberra; 2016 [cited 2021 November 23]. Available from: https://www.canberra.edu.au/research/faculty-research-centres/nmrc/research/mobile-digital-communication-and-health-management/Mobile-Health-Empowering-people-with-type-2-diabetes-using-digital-tools-updated-v2.pdf.
33. Health Insurance Review and Assessment Service. Roles and functions of health insurance review and assessment service [Internet]. Wonju: Health Insurance Review and Assessment Service; 2021 [cited 2021 May 25]. Available from: https://repository.hira.or.kr/handle/2019.oak/2523.
34. Health Insurance Review and Assessment Service. Guidelines on national health insurance benefits coverage for new and innovative healthcare technology. AI-based healthcare technology (medial imaging) & introduction of 3D printing to healthcare technology [Internet]. Wonju: Health Insurance Review and Assessment Service; 2019 [cited 2021 May 25]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020040100100&brdScnBltNo=4&brdBltNo=10255#none.
35. Centers for Medicare & Medicaid Services. Medicare program; revised process for making national coverage determinations. Notice. Fed Regist 2013;78:48164-69.
36. Premera Blue Cross. Medical policy-13.012.500. Prescription digital therapeutics [Internet]. Mountlake Terrace (WA): Premera Blue Cross; 2021 [cited 2021 November 23]. Available from: https://www.premera.com/medicalpolicies/13.01.500.pdf.
37. UK Department of Health and Social Care. Accelerated access review. Final report [Internet]. London: UK Department of Health and Social Care; 2016 [cited 2021 May 20]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/565072/AAR_final.pdf.
39. National Institute for Health and Care Excellence. Process and methods statement for the production of NICE IAPT assessment briefings (IABs) [Internet]. London: National Institute for Health and Care Excellence; 2019 [cited 2021 May 20]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-advice/IAPT/IAB-process-and-methods-statement.pdf.

40. National Institute for Health and Care Excellence. Process and methods statement for the production of NICE IAPT evaluation in practice reports [Internet]. London: National Institute for Health and Care Excellence; 2019 [cited 2021 May 20]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-advice/IAPT/IEPR-process-methods.pdf.

41. National Institute for Health and Care Excellence. Space from depression for treating adults with depression [Internet]. London: National Institute for Health and Care Excellence; 2020 [cited 2021 May 20]. Available from: https://www.nice.org.uk/advice/mib215/resources/space-from-depression-for-treating-adults-with-depression-pdf-228596545322793.

42. Bundesinstitut für Arzneimittel und Medizinprodukte. DiGA directory [Internet]. Bonn: Bundesinstitut für Arzneimittel und Medizinprodukte; 2021 [cited 2021 May 27]. Available from: https://diga.bfarm.de/de/verzeichnis.

43. Ministry of Health, Labour and Welfare of Japan. Handling of medical device insurance coverage, etc. [Internet]. Tokyo: Ministry of Health, Labour and Welfare of Japan; 2019 [cited 2021 April 13]. Available from: https://www.mhlw.go.jp/content/000497471.pdf.

44. Ministry of Health, Labour and Welfare of Japan. Criteria for calculating insurance redemption prices for specified insurance medical materials [Internet]. Tokyo: Ministry of Health, Labour and Welfare of Japan; 2019 [cited 2021 April 13]. Available from: https://www.mhlw.go.jp/content/000497470.pdf.

45. Ministry of Health, Labour and Welfare of Japan. Insurance coverage for medical devices [Internet]. Tokyo: Ministry of Health, Labour and Welfare of Japan; 2020 [cited 2021 April 13]. Available from: https://www.mhlw.go.jp/content/12404000/000693018.pdf.

46. CureApp, Inc. CureApp and Jichi Medical University collaborate on a hypertension therapeutics app Primary endpoint met in Phase III clinical trial in Japan. [Internet]. Tokyo: CureApp, Inc.; 2021 [cited 2021 December 2]. Available from: https://cureapp-en.blogspot.com/2021/03/cureapp-and-jichi-medical-university.html.

47. Medicare Services Advisory Committee. Frequently asked questions [Internet]. [place unknown]: Medicare Services Advisory Committee; 2019 [cited 2021 June 1]. Available from: http://www.mscag.gov.au/iatinternet/msac/publishing.nsf/Content/FAQ-01.

48. Medicare Services Advisory Committee. Process framework [Internet]. [place unknown]: Medicare Services Advisory Committee; 2016 [cited 2021 May 25]. Available from: http://www.mscag.gov.au/internet/msac/publishing.nsf/Content/FFDFEFDA8B25248FCA25801000123AD3/$File/Final%20Process%20Framework.pdf.